157. スタージ・ウェーバー症候群 Sturge-Weber syndrome Clinical trials / Disease details
臨床試験数 : 10 / 薬物数 : 13 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01997255 (ClinicalTrials.gov) | April 2014 | 15/11/2013 | Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) | An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome | Sturge Weber Syndrome | Drug: Everolimus | Baylor College of Medicine | Novartis Pharmaceuticals | Withdrawn | 2 Years | 18 Years | Both | 0 | Phase 2 | United States |